{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:37:03Z","timestamp":1791236223356,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T00:00:00Z","timestamp":1465862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen causing disease outbreaks in Africa and the Arabian Peninsula. The virus has great potential for transboundary spread due to the presence of competent vectors in non-endemic areas. There is currently no fully licensed vaccine suitable for use in livestock or humans outside endemic areas. Here we report the evaluation of the efficacy of a recombinant subunit vaccine based on the RVFV Gn and Gc glycoproteins. In a previous study, the vaccine elicited strong virus neutralizing antibody responses in sheep and was DIVA (<jats:bold>d<\/jats:bold>ifferentiating naturally<jats:bold>i<\/jats:bold>nfected from<jats:bold>v<\/jats:bold>accinated<jats:bold>a<\/jats:bold>nimals) compatible. In the current efficacy study, a group of sheep (<jats:italic>n<\/jats:italic>\u2009=\u20095) was vaccinated subcutaneously with the glycoprotein-based subunit vaccine candidate and then subjected to heterologous challenge with the virulent Kenya-128B-15 RVFV strain. The vaccine elicited high virus neutralizing antibody titers and conferred complete protection in all vaccinated sheep, as evidenced by prevention of viremia, fever and absence of RVFV-associated histopathological lesions. We conclude that the subunit vaccine platform represents a promising strategy for the prevention and control of RVFV infections in susceptible hosts.<\/jats:p>","DOI":"10.1038\/srep27719","type":"journal-article","created":{"date-parts":[[2016,6,14]],"date-time":"2016-06-14T09:56:55Z","timestamp":1465898215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["A Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Confers Full Protection against Rift Valley Fever Challenge in Sheep"],"prefix":"10.1038","volume":"6","author":[{"given":"Bonto","family":"Faburay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha N.","family":"Gaudreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sally","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Shivanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhupinder","family":"Bawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Sunwoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Drolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Morozov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Scott","family":"McVey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen A.","family":"Richt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,14]]},"reference":[{"key":"BFsrep27719_CR1","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2174\/156652405774962263","volume":"5","author":"R Flick","year":"2005","unstructured":"Flick, R. & Bouloy, M. Rift Valley fever virus. Current Molecular Medicine 5, 827\u2013834 (2005).","journal-title":"Current Molecular Medicine"},{"key":"BFsrep27719_CR2","doi-asserted-by":"crossref","unstructured":"Elliott, R. M. e. The Bunyaviridae. Plenum Press, New York, N.Y. (1996).","DOI":"10.1007\/978-1-4899-1364-7"},{"key":"BFsrep27719_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/1469-0691.12163","volume":"19","author":"V Chevalier","year":"2013","unstructured":"Chevalier, V. Relevance of Rift Valley fever to public health in the European Union. Clin Microbiol Infect 19, 705\u2013708, doi: 10.1111\/1469-0691.12163 (2013).","journal-title":"Clin Microbiol Infect"},{"key":"BFsrep27719_CR4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.2987\/10-6070.1","volume":"26","author":"MJ Turell","year":"2010","unstructured":"Turell, M. J., Dohm, D. J., Geden, C. J., Hogsette, J. A. & Linthicum, K. J. Potential for stable flies and house flies (Diptera: Muscidae) to transmit Rift Valley fever virus. J Am Mosq Control Assoc 26, 445\u2013448 (2010).","journal-title":"J Am Mosq Control Assoc"},{"key":"BFsrep27719_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/jme\/tjv093","volume":"52","author":"MJ Turell","year":"2015","unstructured":"Turell, M. J. et al. Potential for Psorophora columbiae and Psorophora ciliata Mosquitoes (Diptera: Culicidae) to Transmit Rift Valley Fever Virus. J Med Entomol 52, 1111\u20131116, doi: 10.1093\/jme\/tjv093 (2015).","journal-title":"J Med Entomol"},{"key":"BFsrep27719_CR6","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3201\/eid1712.111035","volume":"17","author":"AA Grobbelaar","year":"2011","unstructured":"Grobbelaar, A. A. et al. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 17, 2270\u20132276, doi: 10.3201\/eid1712.111035 (2011).","journal-title":"Emerg Infect Dis"},{"key":"BFsrep27719_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","author":"B Botros","year":"2006","unstructured":"Botros, B. et al. Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine. Journal of Medical Virology 78, 787\u2013791 (2006).","journal-title":"Journal of Medical Virology"},{"key":"BFsrep27719_CR8","first-page":"119","volume":"44","author":"JA Coetzer","year":"1977","unstructured":"Coetzer, J. A. & Barnard, B. J. Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with wesselsbron disease and rift valley fever viruses as aetiological agents. Onderstepoort J Vet Res 44, 119\u2013126 (1977).","journal-title":"Onderstepoort J Vet Res"},{"key":"BFsrep27719_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.20506\/rst.26.1.1737","volume":"26","author":"J Lubroth","year":"2007","unstructured":"Lubroth, J. et al. Veterinary vaccines and their use in developing countries. Rev Sci Tech 26, 179\u2013201 (2007).","journal-title":"Rev Sci Tech"},{"key":"BFsrep27719_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","volume":"18","author":"P Pittman","year":"2000","unstructured":"Pittman, P. et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18, 181\u2013189 (2000).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","volume":"53","author":"R Muller","year":"1995","unstructured":"Muller, R. et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 53, 405\u2013411 (1995).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep27719_CR12","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","author":"H Caplen","year":"1985","unstructured":"Caplen, H., Peters, C. J. & Bishop, D. H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 (Pt 10), 2271\u20132277 (1985).","journal-title":"J Gen Virol"},{"key":"BFsrep27719_CR13","doi-asserted-by":"publisher","first-page":"4581","DOI":"10.1016\/j.vaccine.2010.04.085","volume":"28","author":"B Dungu","year":"2010","unstructured":"Dungu, B. et al. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28, 4581\u20134587, doi: 10.1016\/j.vaccine.2010.04.085 (2010).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR14","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1016\/j.vaccine.2011.05.055","volume":"29","author":"B von Teichman","year":"2011","unstructured":"von Teichman, B. et al. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 29, 5771\u20135777, doi: 10.1016\/j.vaccine.2011.05.055 (2011).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR15","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","volume":"58","author":"J Morrill","year":"1997","unstructured":"Morrill, J., Mebus, C. & Peters, C. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. American Journal of Veterinary Research 58, 1104\u20131109 (1997).","journal-title":"American Journal of Veterinary Research"},{"key":"BFsrep27719_CR16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","volume":"58","author":"JC Morrill","year":"1997","unstructured":"Morrill, J. C., Mebus, C. A. & Peters, C. J. Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58, 1110\u20131114 (1997).","journal-title":"Am J Vet Res"},{"key":"BFsrep27719_CR17","first-page":"95","volume":"69","author":"P Hunter","year":"2002","unstructured":"Hunter, P., Erasmus, B. & Vorster, J. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort Journal of Veterinary Research 69, 95\u201398 (2002).","journal-title":"Onderstepoort Journal of Veterinary Research"},{"key":"BFsrep27719_CR18","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0042-6822(89)90365-6","volume":"170","author":"CS Schmaljohn","year":"1989","unstructured":"Schmaljohn, C. S. et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 170, 184\u2013192 (1989).","journal-title":"Virology"},{"key":"BFsrep27719_CR19","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","volume":"14","author":"B Faburay","year":"2014","unstructured":"Faburay, B. et al. A glycoprotein subunit vaccine elicits a strong Rift Valley fever virus neutralizing antibody response in sheep. Vector Borne Zoonotic Dis 14, 746\u2013756 (2014).","journal-title":"Vector Borne Zoonotic Dis"},{"key":"BFsrep27719_CR20","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","volume":"28","author":"SM de Boer","year":"2010","unstructured":"de Boer, S. M. et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 28, 2330\u20132339, doi: 10.1016\/j.vaccine.2009.12.062 (2010).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR21","doi-asserted-by":"publisher","first-page":"4657","DOI":"10.1016\/j.vaccine.2005.08.034","volume":"24","author":"K Spik","year":"2006","unstructured":"Spik, K. et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 24, 4657\u20134666, doi: 10.1016\/j.vaccine.2005.08.034 (2006).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR22","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1743-422x-6-6","volume":"6","author":"N Lagerqvist","year":"2009","unstructured":"Lagerqvist, N. et al. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6, 6, doi: 10.1186\/1743-422x-6-6 (2009).","journal-title":"Virol J"},{"key":"BFsrep27719_CR23","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.virol.2008.12.012","volume":"385","author":"J Naslund","year":"2009","unstructured":"Naslund, J. et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus. Virology 385, 409\u2013415, doi: 10.1016\/j.virol.2008.12.012 (2009).","journal-title":"Virology"},{"key":"BFsrep27719_CR24","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1016\/j.vaccine.2012.03.027","volume":"30","author":"J Kortekaas","year":"2012","unstructured":"Kortekaas, J. et al. Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 30, 3423\u20133429, doi: 10.1016\/j.vaccine.2012.03.027 (2012).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR25","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","volume":"397","author":"RB Mandell","year":"2010","unstructured":"Mandell, R. B. et al. A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397, 187\u2013198, doi: 10.1016\/j.virol.2009.11.001 (2010).","journal-title":"Virology"},{"key":"BFsrep27719_CR26","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.1128\/jvi.00841-11","volume":"85","author":"J Kortekaas","year":"2011","unstructured":"Kortekaas, J. et al. Creation of a nonspreading Rift Valley fever virus. J Virol 85, 12622\u201312630, doi: 10.1128\/jvi.00841-11 (2011).","journal-title":"J Virol"},{"key":"BFsrep27719_CR27","doi-asserted-by":"publisher","first-page":"4204","DOI":"10.1128\/jvi.07104-11","volume":"86","author":"KA Dodd","year":"2012","unstructured":"Dodd, K. A., Bird, B. H., Metcalfe, M. G., Nichol, S. T. & Albarino, C. G. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J Virol 86, 4204\u20134212, doi: 10.1128\/jvi.07104-11 (2012).","journal-title":"J Virol"},{"key":"BFsrep27719_CR28","doi-asserted-by":"publisher","first-page":"e77461","DOI":"10.1371\/journal.pone.0077461","volume":"8","author":"N Oreshkova","year":"2013","unstructured":"Oreshkova, N., van Keulen, L., Kant, J., Moormann, R. J. & Kortekaas, J. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. PLoS One 8, e77461, doi: 10.1371\/journal.pone.0077461 (2013).","journal-title":"PLoS One"},{"key":"BFsrep27719_CR29","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","volume":"24","author":"DB Wallace","year":"2006","unstructured":"Wallace, D. B. et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24, 7181\u20137189, doi: 10.1016\/j.vaccine.2006.06.041 (2006).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR30","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1016\/j.vaccine.2004.10.006","volume":"23","author":"DB Wallace","year":"2005","unstructured":"Wallace, D. B. & Viljoen, G. J. Immune responses to recombinants of the South African vaccine strain of lumpy skin disease virus generated by using thymidine kinase gene insertion. Vaccine 23, 3061\u20133067, doi: 10.1016\/j.vaccine.2004.10.006 (2005).","journal-title":"Vaccine"},{"key":"BFsrep27719_CR31","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1017\/s0950268808001696","volume":"137","author":"MT Heise","year":"2009","unstructured":"Heise, M. T. et al. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 137, 1309\u20131318, doi: 10.1017\/s0950268808001696 (2009).","journal-title":"Epidemiol Infect"},{"key":"BFsrep27719_CR32","doi-asserted-by":"publisher","first-page":"20617","DOI":"10.1038\/srep20617","volume":"6","author":"GM Warimwe","year":"2016","unstructured":"Warimwe, G. M. et al. Chimpanzee Adenovirus Vaccine Provides Multispecies Protection against Rift Valley Fever. Sci Rep 6, 20617, doi: 10.1038\/srep20617 (2016).","journal-title":"Sci Rep"},{"key":"BFsrep27719_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.molimm.2015.02.001","volume":"66","author":"G Lorenzo","year":"2015","unstructured":"Lorenzo, G., Lopez-Gil, E., Warimwe, G. M. & Brun, A. Understanding Rift Valley fever: contributions of animal models to disease characterization and control. Mol Immunol 66, 78\u201388, doi: 10.1016\/j.molimm.2015.02.001 (2015).","journal-title":"Mol Immunol"},{"key":"BFsrep27719_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF01309641","volume":"125","author":"TG Besselaar","year":"1992","unstructured":"Besselaar, T. G. & Blackburn, N. K. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins. Arch Virol 125, 239\u2013250 (1992).","journal-title":"Arch Virol"},{"key":"BFsrep27719_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0923-2516(07)80002-1","volume":"145","author":"TG Besselaar","year":"1994","unstructured":"Besselaar, T. G. & Blackburn, N. K. The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. Res Virol 145, 13\u201319 (1994).","journal-title":"Res Virol"},{"key":"BFsrep27719_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/0923-2516(91)90069-F","volume":"142","author":"TG Besselaar","year":"1991","unstructured":"Besselaar, T. G., Blackburn, N. K. & Meenehan, G. M. Antigenic analysis of Rift Valley fever virus isolates: monoclonal antibodies distinguish between wild-type and neurotropic virus strains. Res Virol 142, 469\u2013474 (1991).","journal-title":"Res Virol"},{"key":"BFsrep27719_CR37","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.virol.2015.12.003","volume":"489","author":"B Faburay","year":"2016","unstructured":"Faburay, B. et al. Development of a sheep challenge model for Rift Valley fever. Virology 489, 128\u2013140, doi: 10.1016\/j.virol.2015.12.003 (2016).","journal-title":"Virology"},{"key":"BFsrep27719_CR38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-1702(97)00097-X","volume":"52","author":"P Vialat","year":"1997","unstructured":"Vialat, P., Muller, R., Vu, T. H., Prehaud, C. & Bouloy, M. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 52, 43\u201350 (1997).","journal-title":"Virus Res"},{"key":"BFsrep27719_CR39","doi-asserted-by":"publisher","first-page":"12901","DOI":"10.1128\/jvi.06046-11","volume":"85","author":"BH Bird","year":"2011","unstructured":"Bird, B. H. et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol 85, 12901\u201312909, doi: 10.1128\/jvi.06046-11 (2011).","journal-title":"J Virol"},{"key":"BFsrep27719_CR40","doi-asserted-by":"publisher","first-page":"e2181","DOI":"10.1371\/journal.pntd.0002181","volume":"7","author":"OA Lihoradova","year":"2013","unstructured":"Lihoradova, O. A. et al. Characterization of Rift Valley fever virus MP-12 strain encoding NSs of Punta Toro virus or sandfly fever Sicilian virus. PLoS Negl Trop Dis 7, e2181, doi: 10.1371\/journal.pntd.0002181 (2013).","journal-title":"PLoS Negl Trop Dis"},{"key":"BFsrep27719_CR41","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1099\/vir.0.051250-0","volume":"94","author":"SV Indran","year":"2013","unstructured":"Indran, S. V. et al. Rift Valley fever virus MP-12 vaccine encoding Toscana virus NSs retains neuroinvasiveness in mice. J Gen Virol 94, 1441\u20131450, doi: 10.1099\/vir.0.051250-0 (2013).","journal-title":"J Gen Virol"},{"key":"BFsrep27719_CR42","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/jvi.06190-11","volume":"86","author":"DR Smith","year":"2012","unstructured":"Smith, D. R. et al. Development of a Novel Nonhuman Primate Model for Rift Valley Fever. Journal of Virology 86, 2109\u20132120, doi: 10.1128\/jvi.06190-11 (2012).","journal-title":"Journal of Virology"},{"key":"BFsrep27719_CR43","first-page":"1741","volume":"vol. 2","author":"CS Schmaljohn","year":"2006","unstructured":"Schmaljohn, C. S. & Nichol, S. T. Bunyaviridae. In Fields Virology, 5th edn, vol. 2, pp. 1741\u20131789. Edited by Knippe, D. M. & Howley, P. M. Philadelphia, PA: Lippincott Williams & Wilkins (2006).","journal-title":"Virology"},{"key":"BFsrep27719_CR44","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.vetmic.2007.07.031","volume":"127","author":"J Paweska","year":"2008","unstructured":"Paweska, J. et al. Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo. Veterinary Microbiology 127, 21\u201328 (2008).","journal-title":"Veterinary Microbiology"},{"key":"BFsrep27719_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vetmic.2006.11.008","volume":"121","author":"J Fafetine","year":"2007","unstructured":"Fafetine, J. et al. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N-protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Veterinary Microbiology 121, 29\u201338 (2007).","journal-title":"Veterinary Microbiology"},{"key":"BFsrep27719_CR46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","volume":"95","author":"T Ikegami","year":"2012","unstructured":"Ikegami, T. Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res 95, 293\u2013310, doi: 10.1016\/j.antiviral.2012.06.001 (2012).","journal-title":"Antiviral Res"},{"key":"BFsrep27719_CR47","doi-asserted-by":"publisher","first-page":"28","DOI":"10.4269\/ajtmh.2010.09-0319","volume":"83","author":"R Sang","year":"2010","unstructured":"Sang, R. et al. Rift Valley fever virus epidemic in Kenya, 2006\/2007: the entomologic investigations. Am J Trop Med Hyg 83, 28\u201337, doi: 10.4269\/ajtmh.2010.09-0319 (2010).","journal-title":"Am J Trop Med Hyg"},{"key":"BFsrep27719_CR48","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1089\/vbz.2012.1285","volume":"13","author":"B Faburay","year":"2013","unstructured":"Faburay, B. et al. Rift Valley fever virus structural and nonstructural proteins: recombinant protein expression and immunoreactivity against antisera from sheep. Vector Borne Zoonotic Dis 13, 619\u2013629, doi: 10.1089\/vbz.2012.1285 (2013).","journal-title":"Vector Borne Zoonotic Dis"},{"key":"BFsrep27719_CR49","first-page":"49","volume":"70","author":"J Paweska","year":"2003","unstructured":"Paweska, J. et al. Indirect enzyme-linked immunosorbent assay for the detection of antibody against Rift Valley fever virus in domestic and wild ruminant sera. Onderstepoort Journal of Veterinary Research 70, 49\u201364 (2003).","journal-title":"Onderstepoort Journal of Veterinary Research"},{"key":"BFsrep27719_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.jviromet.2011.11.025","volume":"179","author":"BS Drolet","year":"2012","unstructured":"Drolet, B. S. et al. Development and evaluation of one-step rRT-PCR and immunohistochemical methods for detection of Rift Valley fever virus in biosafety level 2 diagnostic laboratories. J Virol Methods 179, 373\u2013382, doi: 10.1016\/j.jviromet.2011.11.025 (2012).","journal-title":"J Virol Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep27719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27719","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep27719.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,17]],"date-time":"2024-06-17T16:26:51Z","timestamp":1718641611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep27719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,14]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,6,28]]}},"alternative-id":["BFsrep27719"],"URL":"https:\/\/doi.org\/10.1038\/srep27719","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,14]]},"assertion":[{"value":"1 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27719"}}